Bambec 10mg tablets

Riik: Suurbritannia

keel: inglise

Allikas: MHRA (Medicines & Healthcare Products Regulatory Agency)

Osta kohe

Infovoldik Infovoldik (PIL)
01-05-2018
Toote omadused Toote omadused (SPC)
25-01-2017

Toimeaine:

Bambuterol hydrochloride

Saadav alates:

Mawdsley-Brooks & Company Ltd

ATC kood:

R03CC12

INN (Rahvusvaheline Nimetus):

Bambuterol hydrochloride

Annus:

10mg

Ravimvorm:

Oral tablet

Manustamisviis:

Oral

Klass:

No Controlled Drug Status

Retsepti tüüp:

Valid as a prescribable product

Toote kokkuvõte:

BNF: 03010101

Infovoldik

                                PACKAGE LEAFLET: INFORMATION FOR THE USER
BAMBEC
®
Tablets 10 mg and 20 mg
bambuterol hydrochloride
Read all of this leaflet carefully before you start taking this
medicine because it
contains important information for you.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may
harm them, even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. What Bambec Tablets are and what they are used for
2. What you need to know before you take Bambec Tablets
3. How to take Bambec Tablets
4. Possible side effects
5. How to store Bambec Tablets
6. Contents of the pack and other information
1. What Bambec Tablets are and what they are used for
Bambec Tablets contain bambuterol hydrochloride. They belong to a
group of medicines
called bronchodilators.
•
Bronchodilators work by relaxing the airways of your lungs, making
them wider.
•
Bambec Tablets are used to treat breathing problems in people with
asthma and similar
conditions. Bambec Tablets are used as regular treatment to prevent
expected breathing
problems. Bambec Tablets should not be used alone for the regular
treatment of asthma
or other breathing conditions. Bambec tablets must only be used when
your doctor has
prescribed you another type of medication such as an “inhaled
corticosteroid”, which
helps reduce the swelling and inflammation in your lungs. However,
Bambec Tablets
will not relieve an acute asthma attack that has already started.
2. What you need to know before you take Bambec Tablets
Do not take Bambec Tablets:
If you are allergic to bambuterol hydrochloride or any of the other
ingredients of this
medicine (listed in section 6).
Warnings and precautions
Talk to your doctor or pharmacist before taking Bambec Tablets if:

                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Bambec Tablets 10mg
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 10 mg Bambuterol hydrochloride
Excipient(s) with known effect: Each tablet contains 63 mg of lactose
(as
monohydrate).
For the full list of excipients, see section 6.1
3
PHARMACEUTICAL FORM
Tablet.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Management of asthma, bronchospasm and/or reversible airways
obstruction.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
Bambec is formulated as a tablet and should be taken once daily,
shortly
before bedtime. The dose should be individualised.
Patients must receive optimal anti-inflammatory therapy (e.g. inhaled
corticosteroids, leukotriene receptor antagonists) when using Bambec
for
management of asthma.
Adults:
The recommended starting doses are 10 mg–20 mg. The 10 mg dose may
be
increased to 20 mg if necessary after 1–2 weeks, depending on the
clinical
effect.
In patients who have previously tolerated
β
2
-agonists well, the recommended
starting dose, as well as maintenance dose, is 20 mg.
Elderly:
Dose adjustment is not required in the elderly.
Hepatic Impairment:
SIGNIFICANT HEPATIC DYSFUNCTION: Not recommended because of
unpredictable
conversion to terbutaline.
Renal impairment:
MODERATE TO SEVERELY IMPAIRED RENAL FUNCTION (GFR < 50 ML/MIN): It is
recommended that the starting dose of Bambec should be halved in these
patients.
Paediatric population:
Until the clinical documentation has been completed, Bambec should not
be
used in children.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in
section 6.1. Bambec is presently not recommended for children due to
limited
clinical data in this age group.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
As terbutaline is excreted mainly via the kidneys, the dose of Bambec
should be
halved in patients with an impaired renal function (GFR
≤
50 mL/min).
In patients with liver cirrhosis, and probably in patients with ot
                                
                                Lugege kogu dokumenti
                                
                            

Vaadake dokumentide ajalugu